Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.

Alimentary Pharmacology & Therapeutics
María José CasanovaEVODIS Study Group*

Abstract

The long-term outcome of patients after antitumour necrosis factor alpha (anti-TNF) discontinuation is not well known. To assess the risk of relapse in the long-term after anti-TNF discontinuation. This was an extension of the evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (EVODIS) study (Crohn's disease or ulcerative colitis patients treated with anti-TNFs in whom these drugs were withdrawn after achieving clinical remission) based in the same cohort of patients whose outcome was updated. Clinical remission was defined as a Harvey-Bradshaw index ≤4 points in Crohn's disease, a partial Mayo score ≤2 in ulcerative colitis and the absence of fistula drainage despite gentle finger compression in perianal disease. This was an observational, retrospective, multicenter study. A total of 1055 patients were included. The median follow-up time was 34 months. The incidence rate of relapse was 12% per patient-year (95% confidence interval [CI] = 11-14). The cumulative incidence of relapse was 50% (95% CI = 47-53): 19% at one year, 31% at 2 years, 38% at 3 years, 44% at 4 years and 48% at 5 years of follow-up. Of the 60% patients retreated with the same anti-TNF after relapse, 73% regained remission. O...Continue Reading

References

Mar 8, 1980·Lancet·R F Harvey, J M Bradshaw
May 6, 1999·The New England Journal of Medicine·D H PresentS J van Deventer
Sep 29, 2011·Gastroenterology·Edouard LouisUNKNOWN Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives
Sep 25, 2012·Gastroenterology·Geert D'HaensUNKNOWN International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European
Nov 28, 2012·Alimentary Pharmacology & Therapeutics·T MolnárT Wittmann
Jun 5, 2014·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Armelle ChauvinAurelien Amiot
Jun 25, 2014·Alimentary Pharmacology & Therapeutics·B Pariente, D Laharie
Dec 6, 2014·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Konstantinos PapamichaelMarc Ferrante
Jun 3, 2015·Alimentary Pharmacology & Therapeutics·S Ben-HorinX Roblin
Mar 24, 2016·The American Journal of Gastroenterology·Javier P GisbertMaría Chaparro
Oct 11, 2017·Journal of Clinical Gastroenterology·Shomron Ben-HorinMinhu Chen
Oct 11, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Catherine ReenaersUNKNOWN Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif
Mar 17, 2018·Inflammatory Bowel Diseases·Edouard Louis
Jul 6, 2018·European Journal of Gastroenterology & Hepatology·Sandra Bohn ThomsenAnette Mertz Nielsen
Oct 24, 2018·Scandinavian Journal of Gastroenterology·Ji Min LeeDonghoon Kang
Mar 26, 2019·Scandinavian Journal of Gastroenterology·Steven J BotsMark Löwenberg

❮ Previous
Next ❯

Citations

Jun 11, 2021·Alimentary Pharmacology & Therapeutics·Daniela Pugliese, Alessandro Armuzzi
Jun 11, 2021·Alimentary Pharmacology & Therapeutics·María José CasanovaJavier P Gisbert
Aug 16, 2021·The Lancet. Gastroenterology & Hepatology·Taku Kobayashi, UNKNOWN HABYABUSA Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.